Related Experiment Video

Updated: Mar 23, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

11.1K

The cytokine interleukin-26 as a biomarker in pediatric asthma

Jon R Konradsen1,2,3, Björn Nordlund2,3,4, Bettina Levänen5

  • 1Clinical Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, SE-171 76, Stockholm, Sweden.

Respiratory Research
|April 1, 2016
PubMed

Insights

Interleukin-26 (IL-26) may indicate asthma severity in children without eosinophilic inflammation. Sputum IL-26 levels correlated with disease control and neutrophil counts in this pilot study.

Area of Science:

  • Pulmonology
  • Immunology
  • Biomarker Discovery

Background:

  • Investigated the role of Interleukin-26 (IL-26) in pediatric asthma.
  • Examined associations between IL-26, disease severity, and Th2 inflammation biomarkers.
  • Focused on a cohort of pediatric patients with controlled or uncontrolled asthma.

Discussion:

  • Sputum IL-26 protein concentrations correlated with asthma control in children lacking eosinophilic inflammation markers.
  • IL-26 levels in sputum were associated with blood neutrophil counts.
  • Suggests IL-26's potential as a biomarker for asthma severity in specific pediatric subgroups.

Key Insights:

  • IL-26 is a potential indicator of asthma severity in pediatric patients.
  • This association is particularly relevant in cases without significant Th2-mediated inflammation (e.g., low exhaled nitric oxide, low blood eosinophils).
  • Sputum IL-26 levels reflect disease control and correlate with neutrophil presence.

Outlook:

  • Further research is warranted to validate IL-26 as a reliable biomarker for pediatric asthma.
  • Exploring the precise mechanisms linking IL-26 to asthma pathophysiology in non-Th2 inflammation.
  • Investigating therapeutic strategies targeting IL-26 in specific asthma phenotypes.

Keywords:
AsthmaChildrenEosinophilFENOIL-26NeutrophilSputum

More Related Videos

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

8.1K
Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD22608:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

2.7K

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.8K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K